Investigating dihydroorotate dehydrogenase inhibitor mediated mitochondrial dysfunction in hepatic in vitro models



Jones, Samantha W, Penman, Sophie L ORCID: 0000-0001-5326-1675, French, Neil S ORCID: 0000-0002-9376-3482, Park, B Kevin ORCID: 0000-0001-8384-824X and Chadwick, Amy E ORCID: 0000-0002-7399-8655
(2021) Investigating dihydroorotate dehydrogenase inhibitor mediated mitochondrial dysfunction in hepatic in vitro models. Toxicology in Vitro, 72. p. 105096.

[img] Text
Final Accepted DHODH Inhibitor Mitochondrial Toxicity.pdf - Author Accepted Manuscript

Download (1MB) | Preview

Abstract

Inhibition of dihydroorotate dehydrogenase (DHODH), the rate-limiting enzymatic step in de novo pyrimidine synthesis, has broad immunosuppressive effects in vivo and shows promise as a therapeutic target for the treatment of malignancies, viral infections and auto-immune diseases. Whilst there are numerous DHODH inhibitors under development, leflunomide and teriflunomide are the only FDA approved compounds on the market, each of which have been issued with black-box warnings for hepatotoxicity. Mitochondrial dysfunction is a putative mechanism by which teriflunomide and leflunomide elicit their hepatotoxic effects, however it is as yet unclear whether this is shared by other nascent DHODH inhibitors. The present study aimed to evaluate the propensity for DHODH inhibitors to mediate mitochondrial dysfunction in two hepatic in vitro models. Initial comparisons of cytotoxicity and ATP content in HepaRG® cells primed for oxidative metabolism, in tandem with mechanistic evaluations by extracellular flux analysis identified multifactorial toxicity and moderate indications of respiratory chain dysfunction or uncoupling. Further investigations using HepG2 cells, a hepatic line with limited capability for phase I xenobiotic metabolism, identified leflunomide and brequinar as positive mitochondrial toxicants. Taken together, biotransformation of some DHODH inhibitor species may play a role in mediating or masking hepatic mitochondrial liabilities.

Item Type: Article
Uncontrolled Keywords: Dihydroorotate dehydrogenase, Mitochondria, Dysfunction, DILI, HepaRG®, HepG2
Depositing User: Symplectic Admin
Date Deposited: 18 Jan 2021 14:04
Last Modified: 18 Jan 2023 23:03
DOI: 10.1016/j.tiv.2021.105096
Related URLs:
URI: https://livrepository.liverpool.ac.uk/id/eprint/3114069